Efficacy and Safety of Intravenous Immunoglobulin for Treating Refractory Livedoid Vasculopathy: a Systematic Review

Overview

Journal Ther Adv Chronic Dis

Publisher Sage Publications

Date 2022 May 31

PMID 35634570

Authors

Yimeng Gao

Hongzhong Jin

Affiliations

Soon will be listed here.

Abstract

Introduction: Intravenous immunoglobulin (IVIG) was reported to be the third most used monotherapy in livedoid vasculopathy (LV). There is currently a lack of randomized controlled clinical trials and no standardized therapeutic regimen for IVIG therapy in LV.

Methods: We performed a systematic review of the efficacy and safety of IVIG in treating patients with LV using PubMed, Cochrane, and Embase databases.

Results: Eighty LV patients from 17 articles were included, receiving IVIG therapy at a dose of 1-2.1 g/kg body weight every 4 weeks. The effective rate of IVIG therapy in LV patients was 95% (76/80) in published studies, showing a good clinical response for resolution of pain, skin ulcerations, and neurological symptoms, and reducing the dependence on glucocorticoids and immunosuppressive agents. IVIG therapy was well tolerated, and no severe adverse events were observed.

Conclusion: Overall, to a certain degree, IVIG is probably a safe and effective treatment alternative for refractory LV patients, which still need to be confirmed by large-scale randomized controlled clinical trials.

Citing Articles

Intravenous Immunoglobulins as Immunomodulators in Autoimmune Diseases and Reproductive Medicine.

Velikova T, Sekulovski M, Bogdanova S, Vasilev G, Peshevska-Sekulovska M, Miteva D Antibodies (Basel). 2023; 12(1).

PMID: 36975367 PMC: 10045256. DOI: 10.3390/antib12010020.

Pain Management Options in a Patient with Livedoid Vasculopathy and Peripheral Neuropathy.

Palanisamy N, Chinnappan J, Bachuwa G Eur J Case Rep Intern Med. 2023; 10(1):003727.

PMID: 36819654 PMC: 9930874. DOI: 10.12890/2023_003727.

A comprehensive review on pathogenesis, associations, clinical findings, and treatment of livedoid vasculopathy.

Segui M, Llamas-Velasco M Front Med (Lausanne). 2022; 9:993515.

PMID: 36569162 PMC: 9773082. DOI: 10.3389/fmed.2022.993515.

References

Stangel M, Pul R . Basic principles of intravenous immunoglobulin (IVIg) treatment. J Neurol. 2006; 253 Suppl 5:V18-24. DOI: 10.1007/s00415-006-5003-1. View

Gelfand E . Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med. 2012; 367(21):2015-25. DOI: 10.1056/NEJMra1009433. View

Gascon M, de Carvalho J, de Souza Espinel D, Barros A, Alavi A, Criado P . Quality-of-life impairment in patients with livedoid vasculopathy. J Am Acad Dermatol. 2014; 71(5):1024-6. DOI: 10.1016/j.jaad.2014.06.030. View

Vieira R, Bernardes J, Pinto J, Costa L . Livedoid vasculopathy - a challenging disease. Acta Reumatol Port. 2016; 41(3):273-274. View

Weishaupt C, Strolin A, Kahle B, Kreuter A, Schneider S, Gerss J . Characteristics, risk factors and treatment reality in livedoid vasculopathy - a multicentre analysis. J Eur Acad Dermatol Venereol. 2019; 33(9):1784-1791. DOI: 10.1111/jdv.15639. View

Schanz S, Ulmer A, Fierlbeck G . Intravenous immunoglobulin in livedo vasculitis: a new treatment option?. J Am Acad Dermatol. 2003; 49(3):555-6. DOI: 10.1067/s0190-9622(03)00785-0. View

Micieli R, Alavi A . Treatment for Livedoid Vasculopathy: A Systematic Review. JAMA Dermatol. 2017; 154(2):193-202. DOI: 10.1001/jamadermatol.2017.4374. View

Kofler K, Strolin A, Geiger V, Kofler L . Intravenous Immunoglobulin Therapy in Livedoid Vasculopathy: Retrospective Observation of Clinical Outcome and Patient's Activity Level. J Cutan Med Surg. 2021; 25(5):504-510. PMC: 8474298. DOI: 10.1177/12034754211003525. View

Galeotti C, Kaveri S, Bayry J . IVIG-mediated effector functions in autoimmune and inflammatory diseases. Int Immunol. 2017; 29(11):491-498. DOI: 10.1093/intimm/dxx039. View

10.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. J Clin Epidemiol. 2021; 134:178-189. DOI: 10.1016/j.jclinepi.2021.03.001. View

11.

Bounfour T, Bouaziz J, Bezier M, Petit A, Viguier M, Rybojad M . Intravenous immunoglobulins in difficult-to-treat ulcerated livedoid vasculopathy: five cases and a literature review. Int J Dermatol. 2013; 52(9):1135-9. DOI: 10.1111/j.1365-4632.2012.05826.x. View

12.

Pitarch G, Rodriguez-Serna M, Torrijos A, Oliver V, Fortea J . Treatment of livedoid vasculopathy with short-cycle intravenous immunoglobulins. Acta Derm Venereol. 2005; 85(4):374-5. DOI: 10.1080/00015550510027865. View

13.

Ravat F, Evans A, Russell-Jones R . Response of livedoid vasculitis to intravenous immunoglobulin. Br J Dermatol. 2002; 147(1):166-9. DOI: 10.1046/j.1365-2133.2002.04755.x. View

14.

Kreuter A, Gambichler T, Breuckmann F, Bechara F, Rotterdam S, Stucker M . Pulsed intravenous immunoglobulin therapy in livedoid vasculitis: an open trial evaluating 9 consecutive patients. J Am Acad Dermatol. 2004; 51(4):574-9. DOI: 10.1016/j.jaad.2004.05.003. View

15.

Tuchinda P, Tammaro A, Gaspari A . Successful long-term use of intravenous immunoglobulin to treat livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity. Arch Dermatol. 2011; 147(10):1224-5. DOI: 10.1001/archdermatol.2011.274. View

16.

Yoshioka K, Tateishi C, Kato H, Chen K . Systemic lupus erythematosus with refractory ulcerated livedoid vasculopathy: Successful treatment with intravenous immunoglobulin and warfarin. Clin Case Rep. 2018; 6(11):2045-2047. PMC: 6230605. DOI: 10.1002/ccr3.1803. View

17.

. World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2020): Poster Abstracts. Osteoporos Int. 2021; 31(Suppl 1):133-621. PMC: 7925810. DOI: 10.1007/s00198-020-05696-3. View

18.

Guo Y, Tian X, Wang X, Xiao Z . Adverse Effects of Immunoglobulin Therapy. Front Immunol. 2018; 9:1299. PMC: 6008653. DOI: 10.3389/fimmu.2018.01299. View

19.

Amital H, Levy Y, Shoenfeld Y . Use of intravenous immunoglobulin in livedo vasculitis. Clin Exp Rheumatol. 2000; 18(3):404-6. View

20.

Scarpone R, Meier K, Ghoreschi K, Worm M . Intravenous Immunoglobulins in a Series of 32 Rare and Recalcitrant Immune Dermatoses. Acta Derm Venereol. 2020; 100(17):adv00298. PMC: 9274976. DOI: 10.2340/00015555-3662. View